Dr. Carroll is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1825 4th St
San Francisco, CA 94143Phone+1 415-353-7171Fax+1 415-514-6195
Education & Training
- New York Presbyterian Hospital (Cornell Campus)Residency, Urology, 1984 - 1986
- University of California (San Francisco)Residency, Urology, 1981 - 1984
- University of California (San Francisco)Residency, Surgery, 1979 - 1981
- Georgetown University School of MedicineClass of 1979
Certifications & Licensure
- NY State Medical License 1984 - Present
- CA State Medical License 1980 - 2025
- American Board of Urology Urology
Awards, Honors, & Recognition
- America's Top Doctors Castle Connolly, 2002-2014
- America's Top Doctors for Cancer Castle Connolly, 2005-2013
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013
- Join now to see all
Clinical Trials
- Surgery With or Without Chemotherapy in Treating Patients With Newly Diagnosed or Recurrent Bladder Cancer Start of enrollment: 1996 Dec 01
- Comparison of Combination Chemotherapy Regimens With or Without Cetuximab in Treating Patients Who Have Undergone Surgery For Stage III Colon Cancer Start of enrollment: 2004 Feb 01
- Lycopene or Omega-3 Fatty Acid Nutritional Supplements in Treating Patients With Stage I or Stage II Prostate Cancer Start of enrollment: 2003 Apr 01
- Join now to see all
Publications & Presentations
PubMed
- Determining Long-term Prostate Cancer Outcomes for Active Surveillance Patients Without Early Disease Progression: Implications for Slowing or Stopping Surveillance.Kevin Shee, James Nie, Janet E Cowan, Lufan Wang, Samuel L Washington 3rd
European Urology Oncology. 2025-04-01 - 1 citationsDe-escalation of Monitoring in Active Surveillance for Prostate Cancer: Results from the GAP3 Consortium.Yoichiro Tohi, John M Sahrmann, Jaron Arbet, Takuma Kato, Lui Shiong Lee
European Urology Oncology. 2025-04-01 - 2 citationsHas Active Surveillance for Prostate Cancer Become Safer? Lessons Learned from a Global Clinical Registry.Chris Bangma, Paul Doan, Lin Zhu, Sebastiaan Remmers, Daan Nieboer
European Urology Oncology. 2025-04-01
Journal Articles
- First-in-Human Phase I Study of CTT1057, a Novel 18F Labeled Imaging Agent with Phosphoramidate Core Targeting Prostate Specific Membrane Antigen in Prostate CancerSpencer C Behr, Hao G Nguyen, Thomas A Hope, Kirsten L Greene, Matthew R Cooperberg, Robert R Flavell, Eric J Small, Peter R Carroll, Journal of Nuclear Medicine
Press Mentions
- Improving Prostate Cancer Screening for Transgender WomenJune 26th, 2024
- Transgender Women Are Still at Risk for Prostate CancerApril 30th, 2023
- New PET Imaging Agent Alters Prostate Cancer Plan for More Than 40% of PatientsSeptember 10th, 2021
- Join now to see all
Grant Support
- Effectiveness Of Early Stage Prostate Cancer TreatmentNational Cancer Institute2009–2010
- MALE Reproductive Health Research Career Development ProgramEunice Kennedy Shriver National Institute Of Child Health &Human Development2006–2010
- UCSF Prostate Cancer SporeNational Cancer Institute2004–2008
- Molecular Effects Of Nutrition Supplements In ProstateNational Cancer Institute2005–2007
- Active Surveillance For Early Stage Prostate Cancer: Selection, MonitoringNational Cancer Institute2006
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: